Possibly... But Saito was wrong on VION.OB and GETA.OB. Only time I've seen him right is w/ SNTS.
The thing that scares me about HNAB is the fact that they want to submit an NDA based on a Phase 2 trial, VION tried the same thing, and failed, ended up filing for Ch. 11.
However, HNAB could be a 50%-100%+ gainer in the next few months, so it'd probably be good for a trade or two!
GL!
Visit my biotech investing board!: investorshub.advfn.com/boards/board.aspx?board_id=16653
GLTA.